Thank you for joining Purple Innovation's fourth-quarter 2024 earnings call. A copy of our earnings press release is available on the Investor Relations section of Purple's website at www.Purple.com.

Purple Innovation’s stock rose 20.57% in aftermarket trading despite a slight revenue miss. The company reported improved gross margins and positive adjusted EBITDA for Q4 2024. New product launches ...

Q4 2024 and Recent Clinical & Corporate Highlights ... in research and development expenses. As of December 31, 2024, Purple Biotech had cash and cash equivalents and short-term deposits of ...

Net Revenue: $129 million for Q4, down 11.6% from $145.9 million in the prior year ... 2025 Adjusted EBITDA Guidance: Expected to be flat to up $10 million. Purple Innovation Inc (NASDAQ:PRPL) ...

“Our major value-driving milestones in 2024 included completing successful ... supporting its differentiated benefit,” stated Gil Efron, Purple Biotech (PPBT) CEO. “CM24 met all of its ...

Thank you for joining Purple Innovation's fourth-quarter 2024 earnings call. A copy of our earnings press release is available on the Investor Relations section of Purple's website at www.Purple.com.

Purple Innovation’s stock rose 20.57% in aftermarket trading despite a slight revenue miss. The company reported improved gross margins and positive adjusted EBITDA for Q4 2024. New product ...